Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or
administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent
HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)
Phase:
Phase 2
Details
Lead Sponsor:
Aarhus University Hospital
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Hammersmith Hospitals NHS Trust Herning Hospital Hvidovre University Hospital Odense University Hospital Rigshospitalet, Denmark St Mary's Hospital, London University Hospital of Cologne